Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: A retrospective study of routine clinical use (ANEMONE)
European Journal of Clinical Microbiology & Infectious Diseases | Aug 16, 2018
ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis
Journal of Clinical Endocrinology & Metabolism | Aug 12, 2018
Most read this week